Loading…
Jagsonpal Pharmaceuticals (JAGSNPHARM)₹217.42+0.01%Pharmaceuticals
In the Sep 2026 quarter (standalone), Jagsonpal Pharmaceuticals reported sales of ₹81.09 Cr, up 9.5% from Sep 2025, and net profit of ₹13.02 Cr, up 0.1% year on year. For the year to Mar 2026, sales were ₹287 Cr and net profit ₹43.04 Cr.
Company filings, standalone accounts; latest reported quarter Sep 2026
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 47.10 | 43.08 | 61.09 | 75.10 | 74.06 | 59.06 | 76.12 | 74.06 | 73.08 | 64.08 | 82.15 | 81.09 |
| Expenses | 43.79 | 40.84 | 50.80 | 57.73 | 57.75 | 49.84 | 60.76 | 57.78 | 56.74 | 52.79 | 64.71 | 64.76 |
| Operating Profit | 3.01 | 3.01 | 10.02 | 16.05 | 16.05 | 9.03 | 14.04 | 16.05 | 16.05 | 11.03 | 17.04 | 17.05 |
| OPM % | 7.0% | 6.0% | 16.9% | 21.9% | 20.9% | 15.0% | 19.0% | 21.9% | 21.9% | 16.9% | 21.0% | 20.9% |
| Other Income | 2.99 | 1.99 | −1.99 | 1.99 | 25.95 | 2.99 | 2.99 | 2.99 | 0.99 | 2.99 | 2.99 | 1.99 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.99 | 1.99 | 1.99 | 1.99 | 1.99 | 1.99 | 1.99 | 1.99 | 1.99 | 1.99 |
| Profit before tax | 5.01 | 5.01 | 7.01 | 14.99 | 38.99 | 8.99 | 13.99 | 17.01 | 15.01 | 11.99 | 17.99 | 17.01 |
| Tax % | 25.1% | 22.1% | 25.1% | 25.0% | 17.1% | 24.1% | 25.1% | 25.1% | 25.0% | 25.1% | 25.0% | 25.0% |
| Exceptional items | 0.00 | 0.00 | −2.45 | 0.00 | 18.31 | −0.15 | 0.00 | 0.00 | −1.53 | 0.00 | 0.00 | −0.17 |
| Net Profit | 4.01 | 4.01 | 5.01 | 11.01 | 32.01 | 7.01 | 11.02 | 13.01 | 11.02 | 9.01 | 13.02 | 13.02 |
| EPS (Rs) | 0.59 | 0.53 | 0.80 | 1.72 | 4.81 | 0.98 | 1.61 | 1.88 | 1.63 | 1.30 | 1.99 | 1.90 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 143 | 144 | 127 | 167 | 159 | 188 | 218 | 237 | 209 | 269 | 287 | 300 |
| Expenses | 131 | 137 | 137 | 156 | 149 | 168 | 191 | 202 | 185 | 217 | 228 | 239 |
| Operating Profit | 12.03 | 6.02 | −11.02 | 9.02 | 9.02 | 19.05 | 26.06 | 34.10 | 23.08 | 51.16 | 58.18 | 61.17 |
| OPM % | 8.0% | 4.0% | −9.1% | 6.0% | 5.0% | 10.0% | 12.0% | 14.0% | 11.0% | 19.0% | 19.9% | 20.4% |
| Other Income | 0.99 | 12.97 | 0.00 | 0.99 | 2.99 | 3.99 | 2.99 | 1.99 | 8.98 | 27.96 | 9.98 | 8.96 |
| Interest | 5.01 | 3.01 | 1.01 | 1.01 | 1.01 | 1.01 | 0.00 | 0.00 | 1.01 | 1.01 | 1.01 | 0.00 |
| Depreciation | 2.99 | 1.99 | 0.00 | 0.99 | 0.99 | 0.99 | 1.99 | 0.99 | 1.99 | 7.98 | 8.98 | 7.96 |
| Profit before tax | 4.01 | 13.99 | −12.01 | 9.01 | 9.01 | 21.99 | 26.99 | 34.99 | 30.02 | 69.96 | 57.98 | 62.00 |
| Tax % | 20.1% | 18.1% | −1.0% | 20.0% | 16.1% | 22.1% | 29.1% | 23.1% | 25.1% | 21.1% | 25.1% | — |
| Exceptional items | 0.00 | 12.77 | 0.00 | 0.00 | −0.01 | 0.00 | 0.49 | −1.88 | 0.00 | 23.70 | −1.55 | −1.70 |
| Net Profit | 3.01 | 12.02 | −12.02 | 7.01 | 8.01 | 17.02 | 19.01 | 27.01 | 22.01 | 55.08 | 43.04 | 46.07 |
| EPS (Rs) | 0.49 | 1.80 | −1.75 | 1.09 | 1.19 | 2.59 | 2.87 | 4.07 | 3.39 | 8.32 | 6.42 | 6.82 |
| Dividend payout % | 8.0% | 2.0% | −2.0% | 8.9% | 16.9% | 15.0% | 56.0% | 49.0% | 58.9% | 30.0% | 61.9% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12.99 | 12.98 | 12.97 | 12.98 | 12.98 | 12.98 | 12.98 | 12.98 | 12.98 | 12.98 | 12.97 | 12.98 |
| Reserves | 82.32 | 85.34 | 97.35 | 85.27 | 91.33 | 98.33 | 109 | 120 | 147 | 175 | 228 | 264 |
| Borrowings | 38.93 | 37.89 | 7.99 | 7.98 | 3.99 | 4.99 | 6.99 | 0.00 | 5.98 | 8.98 | 8.97 | 7.98 |
| Other Liabilities | 19.06 | 22.06 | 24.96 | 22.94 | 27.89 | 30.94 | 35.00 | 30.99 | 29.85 | 20.90 | 28.86 | 32.03 |
| Total Liabilities | 154 | 159 | 143 | 130 | 136 | 147 | 164 | 164 | 195 | 217 | 278 | 318 |
| Fixed Assets | 52.09 | 52.15 | 22.07 | 21.03 | 22.05 | 22.05 | 26.07 | 23.04 | 24.05 | 9.02 | 94.15 | 85.18 |
| CWIP | 0.00 | 0.00 | 0.00 | 2.99 | 3.99 | 3.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.04 | 15.05 | 51.14 | 1.01 | 0.00 | 0.00 | 0.00 |
| Other Assets | 102 | 108 | 121 | 105 | 110 | 109 | 123 | 91.24 | 170 | 208 | 184 | 232 |
| Inventories | 33.03 | 40.05 | 48.08 | 51.04 | 33.04 | 29.02 | 30.01 | 30.02 | 21.01 | 15.03 | 15.02 | 15.02 |
| Trade receivables | 44.83 | 41.86 | 38.85 | 24.93 | 20.92 | 20.92 | 12.95 | 15.95 | 20.92 | 10.96 | 12.95 | 16.95 |
| Cash & equivalents | 15.05 | 16.05 | 20.04 | 15.04 | 39.10 | 38.10 | 60.10 | 25.06 | 115 | 148 | 129 | 106 |
| Total Assets | 154 | 159 | 143 | 130 | 136 | 147 | 164 | 164 | 195 | 217 | 278 | 318 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 3.99 | 9.01 | −2.99 | −1.99 | 30.99 | 10.99 | 27.97 | 6.99 | 46.99 | 34.99 | 54.92 | 46.98 |
| Cash from investing activity | 0.00 | −2.01 | 41.03 | −3.01 | −1.01 | −11.01 | −2.01 | −26.01 | −58.02 | −25.03 | −44.99 | −36.05 |
| Cash from financing activity | −1.01 | −6.01 | −33.98 | −1.01 | −6.01 | −1.01 | −6.99 | −18.01 | 0.00 | −9.01 | −12.01 | −11.99 |
| Net cash flow | 2.01 | 1.01 | 5.02 | −6.02 | 24.07 | 0.00 | 19.05 | −36.11 | −11.03 | 2.01 | −2.01 | −1.01 |
| Capex | 0.57 | 2.74 | 0.00 | 3.82 | 2.24 | 2.06 | 0.46 | 1.04 | 0.31 | 0.24 | 0.34 | 0.14 |
| Free cash flow | 3.99 | 5.99 | 39.90 | −4.99 | 29.95 | 11.97 | 27.92 | 5.99 | 47.87 | 34.93 | 89.82 | 46.90 |
| CFO / OP % | 53.1% | 83.1% | −6.0% | 14.1% | 311.1% | 150.1% | 164.0% | 54.1% | 158.1% | 189.0% | 124.1% | 101.1% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 119 | 106 | 100 | 73 | 45 | 49 | 25 | 26 | 32 | 19 | 18 | 22 |
| Inventory days | 175 | 245 | 294 | 306 | 163 | 190 | 133 | 121 | 81 | 67 | 57 | 50 |
| Days payable | 43 | 61 | 57 | 55 | 60 | 77 | 83 | 77 | 67 | 36 | 38 | 41 |
| Cash conversion cycle | 253 | 293 | 340 | 326 | 151 | 165 | 78 | 73 | 49 | 54 | 40 | 34 |
| Working capital days | 67 | 71 | 153 | 148 | 66 | 54 | 31 | 58 | 33 | 51 | 8 | 10 |
| ROCE % | 5.0% | 7.0% | 3.0% | −9.9% | 9.1% | 9.0% | 18.0% | 20.1% | 25.1% | 17.1% | 23.1% | 23.0% |
For the Sep 2026 quarter, Jagsonpal Pharmaceuticals reported sales of ₹81.09 Cr, up 9.5% year on year and net profit of ₹13.02 Cr, up 0.1% year on year. The operating margin was 20.9%.
Jagsonpal Pharmaceuticals' sales for the year to Mar 2026 were ₹287 Cr; over the last twelve months they were ₹300 Cr.
Net profit for the year to Mar 2026 was ₹43.04 Cr, and ₹46.07 Cr over the last twelve months. Earnings per share over the same trailing period were ₹6.82.
Jagsonpal Pharmaceuticals reported borrowings of ₹7.98 Cr at Mar 2026, against cash and equivalents of ₹106 Cr.
Cash from operations was ₹46.98 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹46.90 Cr.